NEW YORK CITY, NY / ACCESS Newswire / November 18, 2026 / On November 13, 2026, Candel Therapeutics (NASDAQ: CADL) shares fell roughly 26% after the Company disclosed that its Biologics License Application (BLA) for aglatimagene in localized prostate cancer is now expected in mid-2027 -- not the fourth quarter of 2026. If you held CADL when that news hit, your losses may be recoverable. Investors who suffered losses are encouraged to submit their CADL loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Candel attributed the delay to "timelines associated with certain assay refinement" and ongoing dialogue with the FDA. The BLA has been tied to Candel's capital raising. In December 2024, the Company announced an $80 million public offering and listed "preparing submission of a Biologics License Application for CAN-2409 in prostate cancer" among its intended uses of proceeds. CAN-2409 is now known as aglatimagene.
In its November 12, 2026 Form 10-Q, Candel stated it "will require additional capital to commercialize aglatimagene in early localized prostate cancer." The investigation focuses on CADL investors who lost money following the delay.
Shareholders who lost money on CADL after the November 12 announcement can request a no-cost review of their losses or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the CADL Investigation
Q: Who is conducting the CADL investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased CADL securities. The firm is nationally recognized and has been ranked in the ISS Top 50 for seven consecutive years.
Q: Who is eligible to participate in the CADL investigation? A: Investors who purchased CADL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did CADL stock drop? A: Shares fell approximately $2.19, or about 26% after the Company disclosed on November 12, 2026 that it now expects to submit its aglatimagene BLA in mid-2027 rather than the fourth quarter of 2026. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: What do CADL investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my CADL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CADL and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
